Patents Assigned to Bergen Teknologieverforing AS
  • B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
    Patent number: 7914785
    Abstract: The present invention relates in a first aspect to a B-cell depleting anti-CD20 antibody or a CD20-binding antibody fragment thereof for the treatment of chronic fatigue syndrome and myalgic encephalomyelitis. In particular, the present invention relates to the use of anti-CD20 monoclonal antibodies or fragments thereof which are preferably humanized for the treatment of chronic fatigue syndrome/myalgic encephalomyelitis in a subject afflicted with said disease.
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: March 29, 2011
    Assignee: Bergen Teknologieverforing AS
    Inventors: Olav Mella, Oystein Fluge